Log in
Enquire now
‌

US Patent 10258679 Recombinant

Patent 10258679 was granted and assigned to Advaxis on April, 2019 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors
Is a
Patent
Patent
0
Current Assignee
Advaxis
Advaxis
0
Date Filed
April 14, 2015
0
Date of Patent
April 16, 2019
0
Patent Applicant
Advaxis
Advaxis
0
Patent Application Number
15306289
0
Patent Citations
‌
US Patent 10010593 Recombinant
‌
US Patent 10016617 Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
Patent Citations Received
‌
US Patent 11446369 Compositions and methods comprising KLK3 or FOLH1 antigen
‌
US Patent 10900044 Listeria-based compositions comprising a peptide minigene expression system and methods of use thereof
0
‌
US Patent 11702664 Listeria-based compositions comprising a peptide minigene expression system and methods of use thereof
0
Patent Inventor Names
Robert Petit
0
Anu Wallecha
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
10258679
0
Patent Primary Examiner
‌
Jana A Hines
0

Find more entities like US Patent 10258679 Recombinant

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.